Trial Profile
Multicenter Phase II Trial of Nintedanib (Vargatef) Plus Docetaxel in Second Line of Treatment in Patients With no Squamous Non Small Cell Lung Cancer Refractory to First Line Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Docetaxel
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms REFRACT
- 01 Nov 2021 Primary endpoint (median progression free survival) has not been met according to the results published in the Lung Cancer
- 01 Nov 2021 Results published in the Lung Cancer
- 09 Aug 2021 Status changed from active, no longer recruiting to completed.